Review
doi: 10.1016/j.molonc.2012.01.009.
Epub 2012 Feb 16.
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design
Affiliations
- PMID: 22386481
- PMCID: PMC5528372
- DOI: 10.1016/j.molonc.2012.01.009
Item in Clipboard
Review
Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design
Mol Oncol.
2012 Apr.
Abstract
With the event of new Molecular targets, clinical trial design requirements to perform these trials are changing. This paper discusses some of the considerations that need to be taken into account when designing a trial, including those trials that assess combinations of targets.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Implementing personalized cancer genomics in clinical trials.Nat Rev Drug Discov. 2013 May;12(5):358-69. doi: 10.1038/nrd3979. Nat Rev Drug Discov. 2013. PMID: 23629504 Review.
-
Maurie Markman on the Groundbreaking TAPUR Trial.Oncology (Williston Park). 2017 Mar 15;31(3):158, 168. Oncology (Williston Park). 2017. PMID: 28299751 No abstract available.
-
[Precision medicine: A major step forward in specific situations, a myth in refractory cancers?].Bull Cancer. 2018 Apr;105(4):375-396. doi: 10.1016/j.bulcan.2018.01.009. Epub 2018 Mar 1. Bull Cancer. 2018. PMID: 29501208 Review. French.
-
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.Am Soc Clin Oncol Educ Book. 2014:71-6. doi: 10.14694/EdBook_AM.2014.34.71. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857062 Review.
-
The SHIVA01 trial: what have we learned?Pharmacogenomics. 2017 Jun;18(9):831-834. doi: 10.2217/pgs-2017-0062. Epub 2017 Jun 8. Pharmacogenomics. 2017. PMID: 28594293 No abstract available.
Cited by
-
The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.Mol Oncol. 2012 Apr;6(2):204-10. doi: 10.1016/j.molonc.2012.02.008. Epub 2012 Mar 16. Mol Oncol. 2012. PMID: 22483534 Free PMC article. Review.
-
Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target.Cancer Sci. 2019 Aug;110(8):2607-2619. doi: 10.1111/cas.14108. Epub 2019 Jul 23. Cancer Sci. 2019. PMID: 31228215 Free PMC article.
-
Individualized drug screening based on next generation sequencing and patient derived xenograft model for pancreatic cancer with bone metastasis.Mol Med Rep. 2017 Oct;16(4):4784-4790. doi: 10.3892/mmr.2017.7213. Epub 2017 Aug 10. Mol Med Rep. 2017. PMID: 28849200 Free PMC article.
-
Identification of pharmacodynamic biomarkers and common molecular mechanisms of response to genotoxic agents in cancer cell lines.Cancer Chemother Pharmacol. 2019 Oct;84(4):771-780. doi: 10.1007/s00280-019-03898-z. Epub 2019 Jul 31. Cancer Chemother Pharmacol. 2019. PMID: 31367787 Free PMC article.
-
A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.Cancer Immunol Immunother. 2018 Apr;67(4):605-613. doi: 10.1007/s00262-018-2116-1. Epub 2018 Jan 11. Cancer Immunol Immunother. 2018. PMID: 29327109 Free PMC article.
References
-
- de Bono, J. , Ashworth, A. , 2010. Translating cancer research into targeted therapeutics. Nature. 467, 543549 - PubMed
-
- Chabner, B. , 2011. Early accelerated approval for highly targeted drugs. N. Engl. J. Med.. 364, 1087–1089. - PubMed
-
- Eisenhauer, E. , Therasse, P. , Bogaerts, J. , 2009. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228–247. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
